Eikon Therapeutics, Inc. Common Stock (EIKN) - Net Assets
Based on the latest financial reports, Eikon Therapeutics, Inc. Common Stock (EIKN) has net assets worth $-879.03 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($594.73 Million) and total liabilities ($1.47 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Eikon Therapeutics, Inc. Common Stock asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-879.03 Million |
| % of Total Assets | -147.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Eikon Therapeutics, Inc. Common Stock - Net Assets Trend (2023–2025)
This chart illustrates how Eikon Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Eikon Therapeutics, Inc. Common Stock total assets for the complete picture of this company's asset base.
Annual Net Assets for Eikon Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual net assets of Eikon Therapeutics, Inc. Common Stock from 2023 to 2025. For live valuation and market cap data, see Eikon Therapeutics, Inc. Common Stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-879.03 Million | -53.70% |
| 2024-12-31 | $-571.93 Million | -67.54% |
| 2023-12-31 | $-341.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Eikon Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 55938200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $41.48 Million | % |
| Total Equity | $-879.03 Million | 100.00% |
Eikon Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Eikon Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DRB - Hicom Bhd
KLSE:1619
|
$538.76 Million |
|
Shenzhen Kexin Communication Technologies Co Ltd
SHE:300565
|
$538.96 Million |
|
Olympic Steel Inc
NASDAQ:ZEUS
|
$538.98 Million |
|
Tactile Systems Technology Inc
NASDAQ:TCMD
|
$539.09 Million |
|
Hangzhou Guotai Environmental Protection Technology Co. Ltd. A
SHE:301203
|
$538.62 Million |
|
Unity Bancorp Inc
NASDAQ:UNTY
|
$538.59 Million |
|
Sebang Global Battery Co Ltd
KO:004490
|
$538.32 Million |
|
Black Cat Syndicate Ltd
AU:BC8
|
$538.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Eikon Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -571,930,000 to -879,034,000, a change of -307,104,000.
- Net loss of 324,248,000 reduced equity.
- New share issuances of 352,053,000 increased equity.
- Other factors decreased equity by 334,909,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-324.25 Million | -36.89% |
| Share Issuances | $352.05 Million | +40.05% |
| Other Changes | $-334.91 Million | -38.1% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Eikon Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-6.32 | $10.91 | x |
| 2024-12-31 | $-10.59 | $10.91 | x |
| 2025-12-31 | $-16.28 | $10.91 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Eikon Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-207.86 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-186.62 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-236.34 Million |
Industry Comparison
This section compares Eikon Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $112,382,454
- Average return on equity (ROE) among peers: -190.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Eikon Therapeutics, Inc. Common Stock (EIKN) | $-879.03 Million | 0.00% | N/A | $538.68 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $11.61 Million | 2.66% | 0.85x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $70.43 Million | -172.28% | 0.74x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $136.85 Million | -50.75% | 0.43x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $7.19 Million | -844.90% | 9.51x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $732.79 Million | 30.90% | 0.62x | $3.61 Billion |
About Eikon Therapeutics, Inc. Common Stock
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and… Read more